ERBB2 and breast cancer: In another recent study, Chakraborty et al. 72 have reported that treatment of MCF-7 cells with a combination of an IGF-1R mAb and the HER2 targeting agents neratinib and trastuzumab resulted in synergistic growth inhibition of these breast cancer cells, supporting the need for further investigations on the therapeutic potential of co-targeting IGF-1R and HER family members in breast cancer.